Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration — Evangelos Terpos (2009) | RDL Network
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
Article 2009 en
Authors
ET
Evangelos Terpos
EK
Eirini Katodritou
ET
E. Tsiftsakis
Abstract
1 min read
Serum cystatin-C is not only a sensitive marker of renal impairment but also reflects tumor burden and is of prognostic value in myeloma. Its reduction after treatment with bortezomib reflects bortezomib's anti-myeloma activity and possibly bortezomib's direct effect on renal function.
Discussion(0)
No comments yet. Be the first to comment.